Aptevo Therapeutics Inc. (NASDAQ:APVO) has a beta value of 2.72 and has seen 1,291,695 shares traded in the last trading session. The company, currently valued at $26.51 Million, closed the last trade at $8.2 per share which meant it lost -$0.7 on the day or -8.48% during that session. The APVO stock price is -74.15% off its 52-week high price of $14.28 and 64.15% above the 52-week low of $2.94. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.08 Million shares traded. The 3-month trading volume is 609.83 Million shares.

The consensus among analysts is that Aptevo Therapeutics Inc. (APVO) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$2.08.

Aptevo Therapeutics Inc. (NASDAQ:APVO) trade information

Despite being -8.48% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the APVO stock price touched $11.73- or saw a rise of 30.09%. Year-to-date, Aptevo Therapeutics Inc. shares have moved -10.51%, while the 5-day performance has seen it change 34.87%. Over the past 30 days, the shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) have changed 22.39%. Short interest in the company has seen 78.21 Million shares shorted with days to cover at 0.13.

Wall Street analysts have a consensus price target for the stock at $32.33, which means that the shares’ value could jump 294.27% from current levels. The projected low price target is $24 while the price target rests at a high of $42. In that case, then, we find that the current price level is +412.2% off the targeted high while a plunge would see the stock lose 192.68% from current levels.

Aptevo Therapeutics Inc. (APVO) estimates and forecasts

Figures show that Aptevo Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -2.38% over the past 6 months, with this year growth rate of -33.53%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 50.5% and 5.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -99.3%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +15.4% over the past 5 years. Earnings growth for 2020 is a modest +54.1% while over the next 5 years, the company’s earnings are expected to increase by 0%.